PE
AXSM icon

Point72 Europe’s Axsome Therapeutics AXSM Stock Holding History

Point72 Europe’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,824
Closed -$3.53M – 737
2025
Q2 		$3.53M Buy
33,824
+18,774
+125% +$1.99M 0.14% 112
2025
Q1 		$1.76M Sell
15,050
-26,684
-64% -$3.04M 0.12% 113
2024
Q4 		$3.53M Buy
41,734
+7,164
+21% +$659K 0.2% 93
2024
Q3 		$3.11M Buy
34,570
+3,829
+12% +$334K 0.2% 90
2024
Q2 		$2.47M Buy
+30,741
New +$2.28M 0.2% 108

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Europe's AXSM Position: Q3 2025 in Review

Point72 Europe sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 33,824 shares — an estimated $3.53M sold.

Point72 Europe first reported a position in AXSM in Q2 2024 and held it in 5 quarters. The position peaked at $3.53M in Q4 2024. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Point72 Europe reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Point72 Europe sold 33,824 Axsome Therapeutics shares in Q3 2025, an estimated $3.53M.
  • Point72 Europe first reported a position in Axsome Therapeutics in Q2 2024 and held it in 5 quarters.
  • Point72 Europe's Axsome Therapeutics position peaked at $3.53M in Q4 2024.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.